S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:INSM

Insmed - INSM Stock Forecast, Price & News

$27.26
+0.51 (+1.91%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$26.87
$27.71
50-Day Range
$17.32
$28.21
52-Week Range
$16.41
$34.44
Volume
1.95 million shs
Average Volume
1.07 million shs
Market Capitalization
$3.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.86

Insmed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
86.6% Upside
$50.86 Price Target
Short Interest
Healthy
5.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.19
Upright™ Environmental Score
News Sentiment
0.40mentions of Insmed in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$8.28 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.40) to ($3.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

376th out of 1,117 stocks

Pharmaceutical Preparations Industry

186th out of 550 stocks

INSM stock logo

About Insmed (NASDAQ:INSM) Stock

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Insmed Stock Performance

INSM opened at $26.75 on Friday. Insmed has a 12-month low of $16.41 and a 12-month high of $34.44. The stock's 50 day moving average price is $21.74 and its two-hundred day moving average price is $22.14. The company has a quick ratio of 5.34, a current ratio of 5.93 and a debt-to-equity ratio of 18.65.

Insmed (NASDAQ:INSM - Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.09. The business had revenue of $65.20 million for the quarter, compared to the consensus estimate of $58.92 million. Insmed had a negative net margin of 188.04% and a negative return on equity of 154.14%. Insmed's quarterly revenue was up 43.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.94) earnings per share. Sell-side analysts predict that Insmed will post -3.4 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Morgan Stanley cut their price target on Insmed from $46.00 to $41.00 and set an "overweight" rating on the stock in a report on Friday, July 15th. Credit Suisse Group lifted their target price on Insmed to $58.00 in a report on Tuesday. Finally, The Goldman Sachs Group cut their price objective on Insmed from $56.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $50.86.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 216,800 shares of the firm's stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $27.84, for a total value of $6,035,712.00. Following the completion of the sale, the chief executive officer now owns 256,716 shares in the company, valued at approximately $7,146,973.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 314,355 shares of company stock valued at $8,279,853 over the last three months. 4.63% of the stock is owned by corporate insiders.

Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Stock News Headlines

Insmed (INSM) to Release Quarterly Earnings on Thursday
Analysts Set Insmed Incorporated (NASDAQ:INSM) PT at $49.67
Insmed (NASDAQ:INSM) Shares Gap Up to $23.65
See More Headlines
Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Company Calendar

Last Earnings
8/04/2022
Today
8/12/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INSM
Employees
373
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$50.86
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$41.00
Forecasted Upside/Downside
+86.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-434,650,000.00
Net Margins
-188.04%
Pretax Margin
-188.82%

Debt

Sales & Book Value

Annual Sales
$188.46 million
Book Value
$0.37 per share

Miscellaneous

Free Float
114,420,000
Market Cap
$3.27 billion
Optionable
Optionable
Beta
1.91

Social Links















INSM Stock - Frequently Asked Questions

Should I buy or sell Insmed stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INSM shares.
View INSM analyst ratings
or view top-rated stocks.

What is Insmed's stock price forecast for 2022?

6 equities research analysts have issued twelve-month target prices for Insmed's stock. Their INSM share price forecasts range from $41.00 to $60.00. On average, they anticipate the company's share price to reach $50.86 in the next year. This suggests a possible upside of 86.6% from the stock's current price.
View analysts price targets for INSM
or view top-rated stocks among Wall Street analysts.

How have INSM shares performed in 2022?

Insmed's stock was trading at $27.24 at the start of the year. Since then, INSM shares have increased by 0.1% and is now trading at $27.26.
View the best growth stocks for 2022 here
.

When is Insmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our INSM earnings forecast
.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.09. The biopharmaceutical company earned $65.20 million during the quarter, compared to analyst estimates of $58.92 million. Insmed had a negative net margin of 188.04% and a negative trailing twelve-month return on equity of 154.14%. The company's revenue for the quarter was up 43.6% on a year-over-year basis. During the same period last year, the business posted ($0.94) EPS.

What guidance has Insmed issued on next quarter's earnings?

Insmed issued an update on its FY 2022 earnings guidance on Thursday, August, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $245.00M-, compared to the consensus revenue estimate of $252.26 million.

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Who are Insmed's major shareholders?

Insmed's stock is owned by many different retail and institutional investors. Top institutional shareholders include Pictet Asset Management SA (3.17%), William Blair Investment Management LLC (2.94%), Loomis Sayles & Co. L P (1.06%), Assenagon Asset Management S.A. (1.05%), Principal Financial Group Inc. (0.87%) and Eagle Asset Management Inc. (0.63%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Goll, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends
.

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $27.26.

How much money does Insmed make?

Insmed (NASDAQ:INSM) has a market capitalization of $3.27 billion and generates $188.46 million in revenue each year. The biopharmaceutical company earns $-434,650,000.00 in net income (profit) each year or ($3.51) on an earnings per share basis.

How many employees does Insmed have?

The company employs 373 workers across the globe.

How can I contact Insmed?

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381.

This page (NASDAQ:INSM) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.